The disclosures of small molecule-based therapeutics included:

• ARV-766: An androgen receptor degrading PROTAC for mCRPC (Arvinas)
• BAY 2965501: A first-in-class a diacylglycerol kinase zeta (lipid kinase) inhibitor for cancer immunotherapy, (Bayer/Nuvisan)
• CFT1946: A CRBN-based oral mutant-selective BRAFV600X degrader (C4 Therapeutics)
• RMC-6291: A tri-complex KRASG12C(ON) inhibitor (Revolution Medicines)
• FX-909: A first-in-class covalent inverse agonist of the PPARG lineage transcription factor (Flare Therapeutics)
• M3913: A potential first-in-class WFS1 transmembrane glycoprotein-targeting unfolded protein response (UPR) inducer (ER stress modulator) (Merck KGaA)
• TNG260: An HDAC1/LSD1/RCOR1 (CoREST) deacetylase complex inhibitor (Tango Therapeutics)
• MRT-2359: A CRBN-based GSPT1 degrader (Monte Rosa Tx)
• BI 907828: An MDM2-p53 protein-protein interaction antagonist related to the Nutlin series (Boehringer Ingelheim)
• EO-3021: A MMAE-based CLDN18.2 ADC (Elevation Oncology)
• ABBV-319: A first-in-class glucocorticoid receptor modulator agonist ADC for B-cell malignancies (AbbVie, SSF)